Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 150
- Registration Number
- NCT00389896
A Comparison Study With Alendronate and Raloxifene in Postmenopausal Women With Osteoporosis (0217-189)
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 400
- Registration Number
- NCT00389740
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1055
- Registration Number
- NCT00383435
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 781
- Registration Number
- NCT00383240
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)(COMPLETED)
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1196
- Registration Number
- NCT00383721
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)
- First Posted Date
- 2006-10-03
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 746
- Registration Number
- NCT00383552
Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 834
- Registration Number
- NCT00381485
Analgesic Treatment Mediated by Arcoxia (0663-093)
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 237
- Registration Number
- NCT00380523
Quality of Life With Arcoxia in Women With Dysmenorrhea (0663-094)
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 337
- Registration Number
- NCT00380627
Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)
Phase 4
Completed
- Conditions
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 91
- Registration Number
- NCT00380705
© Copyright 2024. All Rights Reserved by MedPath